In this interview, Dr. Zaiba Malik talks with Dr. Rahul Khurana about the expanding options for the treatment of retinal vein occlusion (RVO). Given recent data from the CRUISE and BRAVO studies, Dr. Khurana discussess why anti-VEGF therapy, namely ranibizumab (Lucentis) and aflibercept (Eylea), represents the standard of care for nonischemic central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). In clinical practice, he believes anti-VEGF treatment may also be effective in select cases of ischemic vein occlusions.

Financial Disclosures: Dr. Khurana is a paid consultant to Allergan, Genentech, iScience, and Regeneron.